Page last updated: 2024-08-16

temozolomide and yttrium radioisotopes

temozolomide has been researched along with yttrium radioisotopes in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bartolomei, M; Bodei, L; Grana, C; Handkiewicz-Junak, D; Maira, G; Mazzetta, C; Paganelli, G; Rocca, P; Sturiale, C; Villa, G	1
Altavilla, G; Arrigo, C; Baldari, S; Naro, C; Perniciaro, F; Pitini, V	1
Reidy-Lagunes, D; Thornton, R	1
Cengel, KA; Damjanov, N; Metz, DC; Soulen, MC; Teitelbaum, UR; van Houten, D	1

Reviews

1 review(s) available for temozolomide and yttrium radioisotopes

Article	Year
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different? Current oncology reports, 2012, Volume: 14, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbazine; Embolization, Therapeutic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Streptozocin; Sunitinib; Temozolomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors; Yttrium Radioisotopes	2012

Article

Year

Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?

Current oncology reports, 2012, Volume: 14, Issue:3

Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbazine; Embolization, Therapeutic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Streptozocin; Sunitinib; Temozolomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors; Yttrium Radioisotopes

2012

Trials

1 trial(s) available for temozolomide and yttrium radioisotopes

Article	Year
Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2004, Volume: 48, Issue:3 Topics: Antineoplastic Agents, Alkylating; Biotin; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Delivery Systems; Female; Glioblastoma; Humans; Italy; Male; Middle Aged; Radioimmunotherapy; Radiopharmaceuticals; Survival Analysis; Temozolomide; Treatment Outcome; Yttrium Radioisotopes	2004

Article

Year

Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2004, Volume: 48, Issue:3

Topics: Antineoplastic Agents, Alkylating; Biotin; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Delivery Systems; Female; Glioblastoma; Humans; Italy; Male; Middle Aged; Radioimmunotherapy; Radiopharmaceuticals; Survival Analysis; Temozolomide; Treatment Outcome; Yttrium Radioisotopes

2004

Other Studies

2 other study(ies) available for temozolomide and yttrium radioisotopes

Article	Year
Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide. Journal of neuro-oncology, 2007, Volume: 83, Issue:3 Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Radioimmunotherapy; Remission Induction; Salvage Therapy; Survival Rate; Temozolomide; Yttrium Radioisotopes	2007
Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors. Pancreas, 2018, Volume: 47, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Embolization, Therapeutic; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Temozolomide; Thrombocytopenia; Yttrium Radioisotopes	2018

Article

Year

Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide.

Journal of neuro-oncology, 2007, Volume: 83, Issue:3

Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Radioimmunotherapy; Remission Induction; Salvage Therapy; Survival Rate; Temozolomide; Yttrium Radioisotopes

2007

Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors.

Pancreas, 2018, Volume: 47, Issue:8

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Embolization, Therapeutic; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Temozolomide; Thrombocytopenia; Yttrium Radioisotopes

2018